Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ADT plus modified versus standard docetaxel in metastatic prostate cancer patients with poor chemotherapy tolerance
ChiCTR2100046636Phase 4Recruiting
- Sponsor
- The Seventh Affiliated Hospital, Sun Yat-Sen University
- Start
- Jun 2021
- Modality
- Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of docetaxel in prostate cancer (PCa) (2 arms), sponsored by The Seventh Affiliated Hospital, Sun Yat-Sen University. Primary endpoint: Progression-free survival. Started Jun 2021; status: recruiting.
02
Drugs
docetaxel
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on ChiCTR2100046636.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2100046636.